Transvers Miyelit
Özet
Transvers miyelit, spinal kordun bağışıklık mekanizmalarıyla tetiklenen, akut veya subakut başlangıçlı motor ve duyu kayıpları ile sfinkter disfonksiyonuna yol açan demiyelinizan bir hastalıktır. Tanı, spinal inflamasyon bulgularının varlığı ve diğer benzer durumların dışlanması ile konulmakta olup radyolojik görüntüler ve BOS incelemeleri kritik rol oynamaktadır. Tedavide öncelikli olarak yüksek doz steroid kullanımı tercih edilirken, dirençli vakalarda plazma değişimi veya immünglobülin gibi ek yöntemler uygulanmaktadır. Hastalık süreci genellikle monofazik seyretse de prognoz, hastanın klinik bulgularına ve tedaviye yanıtına göre değişiklik gösterebilmektedir.
Transverse myelitis is an immune-mediated demyelinating disease of the spinal cord characterized by the acute or subacute onset of sensory and motor deficits along with sphincter dysfunction. Diagnosis relies on confirming spinal cord inflammation while excluding other potential conditions through spinal imaging and cerebrospinal fluid analysis. Management typically involves high-dose steroid therapy, with plasma exchange or other immunosuppressive treatments reserved for resistant cases. Although the condition is often monophasic, patient outcomes vary significantly based on the severity of symptoms and the timeliness of clinical intervention.
Referanslar
Scott TF, Frohman EM, De Seze J, et al. Evidence-based guideline: clinical evaluation and treatment of transverse miyelitis. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2011; 77(24):2128-2134.
Banwell B, Kennedy J, Sadovnick D, et al. Incidence of acquired demyelination of the CNS in Canadian children. Neurology. 2009; 72(3):232-239.
Thomas T, Branson HM, Verhey LH, et al. The demographic, clinical, and magnetic resonance imaging (MRI) features of transverse miyelitis in children. J Child Neurol. 2012;27(1):11-21.
Awad A, Stave O. Idiopathic transverse miyelitis and neuromiyelitis optica: clinical profiles, pathophysiology and therapeutic choices. Curr Neuropharmacol. 2011;9(3):417-428.
Popa C, Popa F, Grigorean VT and et al. Vascular dysfunctions following spinal cord injury. J Med Life. 2010;3(3):275-285.
Absoud M, Greenberg BM, Lim M and et al. Pediatric transverse miyelitis. Neurology. 2016;87(9 Suppl 2):S46-52.
Chabas D, Pidcock F, Sebire G. What is acute transverse miyelitis in children? In: Chabas D, Waubant E, eds. Demyelinating Disorders of the Central Nervous System in Childhood. Cambridge, NY: Cambridge University Press; 2011: 243-254.
Borchers AT, Gershwin ME. Transverse miyelitis. Autoimmun Rev. 2012;11(3):231-248.
Gozzard P, Orr D, Sanderson F, Sandberg M, Kennedy A. Acute transverse miyelitis as a rare manifestation of Campylobacter diarrhoea with concomitant disruption of the blood brain barrier. J Clin Neurosci. 2012;19(2):316-318.
Isabelle Korn-Lubetzki , Marina Dano, David Raveh. H1N1 vaccine-related acute transverse miyelitis. Isr Med Assoc J. 2011;13(4):249-50.
Ural S, Özer B, Gelal F and et al. Transverse miyelitis associated with toxocariasis and the importance of locally produced antibodies for diagnosis. Mikrobiyol Bul. 2016;50(3):478-83.
Rodríguez Y, Rojas M, Pacheco Y and et al. Guillain-Barre syndrome, transverse miyelitis and infectious diseases. Cell Mol Immunol. 2018;15(6):547-562.
Marchioni E, Ravaglia S, Montomoli C, et al. Postinfectious neurologic syndromes: a prospective cohort study. Neurology. 2013;80:882–889.
Andre JB, Bammer R. Advanced diffusion-weighted magnetic resonance imaging techniques of the human spinal cord. Top Magn Reson Imaging. 2010;21(6):367-378.
Calabra F, Jinkins JR. MRI of radiation miyelitis: a report of a case treated with hyperbaric oxygen. Eur Radiol. 2000;10(7): 1079-1084.
Habek M, Adamec I, Brinar VV. Spinal cord tumor versus transverse miyelitis. Spine J. 2011;11(12):1143-1145.
Barkovich A, Moore K, Jones B and et al. Intramedullary space. In: Diagnostic Imaging Pediatric Neuroradiology. Altona, Manitoba, Canada: Amirsys Book; 2010:1-30.
Pui MH. Gadolinium-enhanced MR angiography of spinal arteriovenous malformation. Clin Imaging. 2004;28(1):28-32.
Alper G, Petropoulou KA, Fitz CR, Kim Y. Idiopathic acute transverse miyelitis in children: an analysis and discussion of MRI findings. Mult Scler. 2011;17(1):74-80.
Hacohen Y, Absoud M, Deiva K, et al. Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children. Neurol Neuroimmunol Neuroinflamm 2015;2:e81.
Absoud M, Lim MJ, Appleton R, et al. Paediatric neuromiyelitis optica: clinical, MRI of the brain and prognostic features. J Neurol Neurosurg Psychiatry. 2015;86: 470–472.
Suthar R, Sankhyan N, Sahu JK and et al. Acute transverse miyelitis in childhood: A single centre experience from North India.. Eur J Paediatr Neurol. Eur J Paediatr Neurol. 2016; 20(3):352-60.
Defresne P, Meyer L, Tardieu M and et al. Efficacy of high dose steroid therapy in children with severe acute transverse miyelitis. J Neurol Neurosurg Psychiatry. 2001; 71(2):272-4
WolfVL, LupoPJ, LotzeTE.Pediatric acute transverse miyelitis overview and differential diagnosis. J Child Neurol. 2012; 27(11): 1426-36.
Bigi S, Banwell B, Yeh EA. Outcomes after early Administration of plasma exchange in pediatric central nervous system inflammatory demyelination. J Child Neurol 2015; 30:874–880.
West TW. Transverse miyelitis-a review of the presentation, diagnosis, and initial management. Discov Med. 2013;16(88):167-77.
Kalra V. Childhood acute transverse miyelitis: clinical profile, outcome, and association with antiganglioside antibodies. J Child Neurol. 2009; 24(4):466-471.
